According to the Associated Press, Eli Lilly and Co. spent $2.5 million in the first quarter lobbying the federal government on access to foreign markets, tax issues and a host of other topics. The Indianapolis-based drugmaker raised its spending 8 percent from the $2.3 million that it spent in the first quarter of last year. It also spent 70 percent more than the $1.5 million recorded in the final quarter of 2010, according to lobbying reports filed with the House of Representatives. The maker of the antipsychotic Zyprexa and the antidepressant Cymbalta lobbied on pricing reforms in Germany and Greece and market access issues in Poland and Romania, among other overseas topics. It also lobbied on food safety, and veterinary medicine and biologics. The drugmaker faces the expiration later this year of patents protecting its top seller, Zyprexa, from generic competition. Other key drugs also will lose patent protection in the next few years.